Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueInventory Average

RedHill Biopharma (RDHL) EBITDA Margin (2016 - 2023)

Historic EBITDA Margin for RedHill Biopharma (RDHL) over the last 12 years, with Q2 2023 value amounting to 2992.87%.

  • RedHill Biopharma's EBITDA Margin rose 29290400.0% to 2992.87% in Q2 2023 from the same period last year, while for Jun 2023 it was 221.67%, marking a year-over-year decrease of 2104700.0%. This contributed to the annual value of 181.69% for FY2024, which is 3972600.0% down from last year.
  • Per RedHill Biopharma's latest filing, its EBITDA Margin stood at 2992.87% for Q2 2023, which was up 29290400.0% from 808.0% recorded in Q1 2023.
  • In the past 5 years, RedHill Biopharma's EBITDA Margin registered a high of 2992.87% during Q2 2023, and its lowest value of 4585.97% during Q4 2019.
  • Its 5-year average for EBITDA Margin is 84.22%, with a median of 76.41% in 2022.
  • Its EBITDA Margin has fluctuated over the past 5 years, first soared by 39894700bps in 2020, then tumbled by -15136000bps in 2021.
  • Quarter analysis of 5 years shows RedHill Biopharma's EBITDA Margin stood at 4585.97% in 2019, then soared by 87bps to 596.5% in 2020, then surged by 81bps to 110.43% in 2021, then plummeted by -888bps to 1090.87% in 2022, then soared by 374bps to 2992.87% in 2023.
  • Its EBITDA Margin was 2992.87% in Q2 2023, compared to 808.0% in Q1 2023 and 1090.87% in Q4 2022.